Zosano Pharma Corporation is a biopharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications.
Zosano (formely known as The Macroflux Company) was as an internal venture within Alza (J&J), a pioneer in the field of drug delivery systems. In 2006, the internal venture became an independent company. Zosano is funded by New Enterprise Associates, Nomura Phase4 Ventures and ProQuest Investments, all well-recognized leaders in the venture capital healthcare arena. Zosano aims to develop products independently and is also actively pursuing strategic licensing and co-development arrangements. Zosano is a fully integrated development company, including a cGMP manufacturing capability. Our management team has extensive experience leading research, development, and operational activities within successful pharmaceuticals and much of our core staff came from Alza (J&J). Zosano’s patent portfolio is both deep and broad covering application and delivery, formulation, pharmacokinetics, array design and manufacturing.
Zosano is advancing a pipeline of drug candidates based on the ZP Patch Technology – a proprietary transdermal delivery technology capable of delivering peptides, proteins, small molecules and vaccines by permeating the skin’s outer layer and ensuring significant and rapid therapeutic effect. This technology offers several key benefits, including needle-free delivery, a self-administered patch, rapid onset of action and room temperature storage. Zosano’s transdermal delivery technology has been clinically tested in over 400 and demonstrated technical feasibility with approximately 30 compounds.